|
Re: New Apabetalone Fabry Disease Publication
|
6
|
Resverlogix Corp.
|
Apr 29, 2022 01:28PM
|
|
There is a new update on the COVID program which can be found here:
|
6
|
Resverlogix Corp.
|
May 18, 2021 12:07PM
|
|
Re: Presentation is gone
|
6
|
Resverlogix Corp.
|
May 16, 2021 03:21PM
|
|
Re: got this & sent a response/follow up minutes before …
|
6
|
Zenith Epigenetics
|
Dec 12, 2023 11:03AM
|
|
Re: Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
|
6
|
Resverlogix Corp.
|
Mar 18, 2022 09:47AM
|
|
Re: Todays presentation
|
6
|
Resverlogix Corp.
|
May 12, 2021 02:38PM
|
|
Re: Why wouldn't our CEO Donald McCaffrey address his shareholders during these troubling times?
|
6
|
Resverlogix Corp.
|
Apr 27, 2020 03:36PM
|
|
Re: Momentum Players and Agoracom.com’s Rules
|
6
|
Resverlogix Corp.
|
Dec 21, 2021 03:38PM
|
|
could they be running the Brazil Trial now?
|
7
|
Resverlogix Corp.
|
Jul 21, 2021 12:50PM
|
|
Re: The jaded group of posters
|
7
|
Resverlogix Corp.
|
Nov 01, 2021 01:41PM
|
|
Re: Finance
|
7
|
Resverlogix Corp.
|
Feb 11, 2021 11:17AM
|
|
wasn't expecting to much of a response - here it is..
|
7
|
Resverlogix Corp.
|
Feb 08, 2022 01:01PM
|
|
Re: Presentation May 12th
|
7
|
Resverlogix Corp.
|
May 06, 2021 12:09PM
|
|
Re: COVID 19 / varients
|
7
|
Resverlogix Corp.
|
Apr 10, 2022 08:58PM
|
|
Resverlogix to Hold BETonMACE Conference Call and Webcast on November 18, 2019
|
7
|
Resverlogix Corp.
|
Nov 12, 2019 09:22AM
|
|
Re: Last day of June.
|
7
|
Resverlogix Corp.
|
Jul 02, 2021 11:55AM
|
|
Re: Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
|
7
|
Resverlogix Corp.
|
Mar 18, 2022 12:08PM
|
|
https://scr.zacks.co...
|
7
|
Zenith Epigenetics
|
May 04, 2020 10:59AM
|
|
maybe Zen will go first?
|
7
|
Resverlogix Corp.
|
May 04, 2020 11:06AM
|
|
Re: Maybe timing is everything…
|
7
|
Resverlogix Corp.
|
Jun 02, 2023 05:20PM
|
